Focus: Erasca is a public oncology-focused biotech company headquartered in San Diego developing targeted cancer therapies, primarily small-molecule kinase inhibitors for solid tumors and hematologic malignancies. The company operates as a clinical-stage player with a diversified pipeline and recent Big Pharma partnership validation.
Profile data last refreshed 1h ago · AI intelligence enriched 2mo ago
Stable — net -4 jobs in 30d
2 added, 6 removed. Backfill posture.
Erasca is a suitable choice for early-to-mid career oncology scientists or clinical developers seeking hands-on pipeline work and partnership exposure, but financial runway and minimal hiring suggest career stability risks without near-term clinical catalysts or capital raises.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Erasca
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Erasca's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Erasca stock gains visibility as FDA fast tracks ERAS-0015 - ad-hoc-news.de
Erasca stock gains visibility as FDA fast tracks ERAS-0015 ad-hoc-news.de
Erasca Wins FDA Fast Track for ERAS-0015 Pan-RAS Drug - Zenopa
Erasca Wins FDA Fast Track for ERAS-0015 Pan-RAS Drug Zenopa
The Race to Develop More Medicines Like the New Pancreatic Cancer Drug - The New York Times
The Race to Develop More Medicines Like the New Pancreatic Cancer Drug The New York Times
Erasca reports 57% preliminary response in patients with later-line KRAS G12X pancreatic cancer - Stock Titan
Erasca reports 57% preliminary response in patients with later-line KRAS G12X pancreatic cancer Stock Titan
Attention Long-Term Shareholders of ARS Pharmaceuticals, - GlobeNewswire
Attention Long-Term Shareholders of ARS Pharmaceuticals, GlobeNewswire
Gainey McKenna files Erasca class action over ERAS-0015 patent risks - scanx.trade
Gainey McKenna files Erasca class action over ERAS-0015 patent risks scanx.trade
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial.
Exposure-Response Analysis of Repotrectinib to Support the Dose Recommendation for Patients With ROS1-Positive NSCLC or NTRK-Positive Solid Tumors.
Showing 5 of 8 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo